iBio, Inc. (NYSEAMERICAN:IBIO) Sees Significant Increase in Short Interest

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 902,500 shares, an increase of 98.7% from the February 13th total of 454,200 shares. Currently, 9.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 395,800 shares, the days-to-cover ratio is currently 2.3 days.

iBio Stock Down 1.0 %

Shares of IBIO stock traded down $0.05 during trading on Friday, hitting $5.08. The company had a trading volume of 300,537 shares, compared to its average volume of 523,103. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04. The business’s 50-day simple moving average is $3.45. iBio has a 52 week low of $1.05 and a 52 week high of $6.89.

About iBio

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.